期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Current Atherosclerosis Reports LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 5.2 Speed 7.0 | ||||||||||||||||
期刊簡稱 | CURR ATHEROSCLER REP | ||||||||||||||||
ISSN | 1523-3804 | ||||||||||||||||
E-ISSN | 1534-6242 | ||||||||||||||||
h-index | 66 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 3.50%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | https://www.springer.com/11883 | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/athe | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Springer US | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | US | ||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||
創刊年 | 1999 | ||||||||||||||||
每年文章數 | 106每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 25.45% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1523-3804%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Current Atherosclerosis Reports] 的評論 | 撰寫評論 |
作者: 宫古鸿羲 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-29 19:18:29 評論於 Review speed: 6.0 | Submission hit rate: 75.0 Research direction emphasis: Vascular surgery; Non-solicited review; Aortic aneurysm experience sharing: self-submitted review, delayed by editor for over three months, reviewers took about a month to review and accepted the submission(0) 讚! | 宫古鸿羲 |
作者: 桃花彩萱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-04-13 10:01:49 評論於 Please translate the following paragraph into English and Japanese, and use ":" and ":" as headings(0) 讚! | 桃花彩萱 |
作者: 残月元纬 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-16 12:58:57 評論於 Are all review articles commissioned?(0) 讚! | 残月元纬 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 16:13:09 評論於 According to the requirements set by the journal's author guidelines, it should be uploaded(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 09:39:15 評論於 Due to the many factors that can affect the efficacy of animal experiments or clinical treatments, unless the results clearly show a synergistic effect greater than the sum of the effectiveness of each drug, it is generally referred to as an enhancing effect(0) 讚! | 维尔娜菲茨杰拉德 |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 21:18:16 評論於 How to determine whether two drugs have synergistic or additive effects?(0) 讚! | Oswald Edie |
作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 16:29:04 評論於 Are there any requirements for submitting an article?(0) 讚! | 深渊兴业 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 08:26:11 評論於 The past was fine, but the current downward trend is really scary. I hope to get back to the 3-point level next year, but it might be too difficult(0) 讚! | 凌霄高洁 |
作者: 匿名 領域: 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2013-03-25 11:27:00 評論於 Influence factor 2.664 Still a good journal mainIt is the study of atherosclerosis that has recently been done as a pathway mechanism. So I paid attention to this journal(0) 讚! | 匿名 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-11-28 23:24:47 評論於 Can we achieve a score of 3 points next year? Let's discuss(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us